SCHEMBL23510637

SCHEMBL23510637

O=C1NC(S)=N/C1=C\c1ccc2ncsc2c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 19/20 0.64
▸ CLK4 Q9HAZ1 18/20 0.64
▸ DYRK1A Q13627 18/20 0.64
▸ DYRK2 Q92630 18/20 0.64
▸ DYRK1B Q9Y463 18/20 0.64
▸ CLK2 P49760 16/20 0.64
▸ DYRK3 O43781 15/20 0.64
▸ CLK3 P49761 13/20 0.64
▸ DYRK4 Q9NR20 12/20 0.64
▸ GSK3B P49841 10/20 0.64
▸ CSNK2A2 P19784 2/20 0.57
▸ CSNK2B P67870 2/20 0.57
▸ CSNK2A1 P68400 2/20 0.57
▸ PIK3CD O00329 1/20 0.56
▸ PRKCB P05771 1/20 0.56
▸ PIK3CA P42336 1/20 0.56
▸ PIK3CG P48736 1/20 0.56
▸ HASPIN Q8TF76 1/20 0.56
▸ CSNK1E P49674 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23970084 0.86 CLK1 (0.60) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL30144962 0.86 CLK1 (0.60) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL25590185 0.85 CLK1 (0.64) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL28843077 0.85 CLK1 (0.64) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL23970074 0.85 CLK1 (0.64) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL23970056 0.84 CLK1 (0.58) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL28842886 0.83 CLK1 (0.60) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL23510493 0.83 CLK1 (0.60) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL30145002 0.83 CLK1 (0.60) CLK1CLK4DYRK1ADYRK2DYRK1B
SCHEMBL23970473 0.81 CLK1 (0.72) CLK1CLK4DYRK1ADYRK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
EP-3904354-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2021-11-03 — — EP disclosed
WO-2021115489-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed
WO-2021114314-A1 NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES TONGJI UNIVERSITY (CN) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 CLK1 2884/4885CLK4 1817/4885DYRK1A 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback